Zacks Research Upgrades Citius Pharmaceuticals (NASDAQ:CTXR) to Hold

Citius Pharmaceuticals (NASDAQ:CTXR) was upgraded by investment analysts at Zacks Research to a “hold” rating in a research report issued on Tuesday,Zacks.com reports.

CTXR has been the topic of several other reports. Weiss Ratings reaffirmed a “sell (e+)” rating on shares of Citius Pharmaceuticals in a research report on Friday, March 27th. HC Wainwright reaffirmed a “buy” rating and issued a $4.00 price target on shares of Citius Pharmaceuticals in a research report on Monday. Finally, D. Boral Capital reaffirmed a “buy” rating and issued a $6.00 price target on shares of Citius Pharmaceuticals in a research report on Wednesday, March 11th. Two research analysts have rated the stock with a Buy rating, three have assigned a Hold rating and one has issued a Sell rating to the company. According to data from MarketBeat, the company has a consensus rating of “Hold” and a consensus target price of $5.00.

Citius Pharmaceuticals Price Performance

Shares of Citius Pharmaceuticals stock opened at $0.58 on Tuesday. The firm has a market cap of $15.92 million, a price-to-earnings ratio of -0.27 and a beta of 1.05. Citius Pharmaceuticals has a 52-week low of $0.48 and a 52-week high of $2.48. The stock has a 50-day simple moving average of $0.77 and a 200-day simple moving average of $0.89.

Citius Pharmaceuticals (NASDAQ:CTXR) last announced its quarterly earnings results on Friday, May 15th. The company reported ($0.95) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.28) by ($0.67). The firm had revenue of $1.67 million during the quarter, compared to analyst estimates of $10.23 million. As a group, equities research analysts predict that Citius Pharmaceuticals will post -1.87 earnings per share for the current year.

Institutional Inflows and Outflows

Several institutional investors have recently added to or reduced their stakes in CTXR. XTX Topco Ltd bought a new stake in shares of Citius Pharmaceuticals during the second quarter valued at approximately $32,000. NewEdge Advisors LLC bought a new stake in shares of Citius Pharmaceuticals during the second quarter valued at approximately $40,000. Asset Advisory Group Inc. bought a new stake in shares of Citius Pharmaceuticals during the fourth quarter valued at approximately $46,000. Finally, Heights Capital Management Inc. bought a new stake in shares of Citius Pharmaceuticals during the fourth quarter valued at approximately $622,000. 16.88% of the stock is owned by institutional investors.

Citius Pharmaceuticals News Roundup

Here are the key news stories impacting Citius Pharmaceuticals this week:

• Positive Sentiment: HC Wainwright reaffirmed a Buy rating on Citius Pharmaceuticals and maintained a $4.00 price target, signaling meaningful upside potential from current levels. Citius Pharmaceuticals’ (CTXR) “Buy” Rating Reaffirmed at HC Wainwright
• Neutral Sentiment: The firm also issued updated earnings estimates for FY2026 and FY2027, with expectations for ongoing losses, including FY2026 EPS of ($1.87) and FY2027 EPS of ($0.81). While these forecasts show improvement over time, they still reflect a pre-profit company. HC Wainwright earnings estimate updates for Citius Pharmaceuticals
• Neutral Sentiment: HC Wainwright’s quarterly projections for Citius Pharmaceuticals remain negative across the forecast period, including Q3 2026 EPS of ($0.36), Q4 2026 EPS of ($0.25), Q1 2027 EPS of ($0.28), Q2 2027 EPS of ($0.20), Q3 2027 EPS of ($0.19), and Q4 2027 EPS of ($0.16). HC Wainwright quarterly earnings estimates for Citius Pharmaceuticals

Citius Pharmaceuticals Company Profile

Citius Pharmaceuticals is a clinical‐stage specialty pharmaceutical company focused on the development and commercialization of critical care products and novel drug delivery systems. Headquartered in Cranford, New Jersey, the company aims to address unmet medical needs in acute care, hospital‐acquired infections and subcutaneous delivery of biologics. Citius operates as a Delaware corporation and trades on the NASDAQ under the symbol CTXR.

One of the company’s leading assets is Mino-Lok, an antibiotic lock solution designed to treat catheter‐related bloodstream infections without catheter removal.